The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis
Open accessAbstract
Immune responses to persistent viral infections and cancer often fail because of intense regulation of antigen-specific T cells—a process referred to as immune exhaustion. The mechanisms that underlie the induction of exhaustion are not completely understood. To gain novel insights into this process, we simultaneously examined the dynamics of virus-specific CD8+ and CD4+ T cells in the living spleen by two-photon microscopy (TPM) during the establishment of an acute or persistent viral infection. We demonstrate that immune exhaustion during viral persistence maps anatomically to the splenic marginal zone/red pulp and is defined by prolonged motility paralysis of virus-specific CD8+ and CD4+ T cells. Unexpectedly, therapeutic blockade of PD-1–PD-L1 restored CD8+ T cell motility within 30 min, despite the presence of high viral loads. This result was supported by planar bilayer data showing that PD-L1 localizes to the central supramolecular activation cluster, decreases antiviral CD8+ T cell motility, and promotes stable immunological synapse formation. Restoration of T cell motility in vivo was followed by recovery of cell signaling and effector functions, which gave rise to a fatal disease mediated by IFN-γ. We conclude that motility paralysis is a manifestation of immune exhaustion induced by PD-1 that prevents antiviral CD8+ T cells from performing their effector functions and subjects them to prolonged states of negative immune regulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 5×
“These mutations afford CL13 the ability to es tablish systemic persistence, which results in the engagement of immune dampening pathways such as the PD1 (Barber et al., 2006) and IL10 (Brooks et al., 2006b; Ejrnaes et al., 2006) that induce T cell exhaustion (Wherry, 2011).”
BackgroundInfluentialRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
The Immunological Synapse: A Molecular Machine Controlling T Cell Activation
Grakoui, A., Bromley, S. K., Sumen, C., Davis, M. M., Shaw, A. S., Allen, P. M., & Dustin, M. L. (1999) · Science · doi:10.1126/science.285.5425.221 · Cited by 3,102
Self-citationPD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Cited by
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
“Current studies have suggested that PD-1 activation suppresses T cell receptor (TCR) signaling (21-23), CD28 costimulatory signaling (24), ICOS costimulatory signaling (25), or a combination of pathways.”
BackgroundMolecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,171
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Barrin, S., Kantari-Mimoun, C., Bercovici, N., Guérin, M., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720948115 · Cited by 919
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
Schietinger, A., & Greenberg, P. D. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.001 · Cited by 673
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
Nguyen, L. T., & Ohashi, P. S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3790 · Cited by 627
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.018 · Cited by 571
Dustin, M. L. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0161 · Cited by 502
“destabilization in autoimmune and delayed-type hypersensitivity (93, 94), but stabilization in antiviral responses (95).”
BackgroundSelf-citationGenetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A., & Wherry, E. J. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142237 · Cited by 467
PD-1 Controls Follicular T Helper Cell Positioning and Function
Shi, J., Hou, S., Fang, Q., Liu, X., Liu, X., & Qi, H. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.012 · Cited by 449
Staron, M. M., Gray, S. M., Marshall, H. D., Parish, I. A., Chen, J. H., Perry, C. J., Cui, G., Li, M. O., & Kaech, S. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.013 · Cited by 385
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Neesse, A., Bauer, C. A., Öhlund, D., Lauth, M., Buchholz, M., Michl, P., Tuveson, D. A., & Gress, T. M. (2019) · Gut · doi:10.1136/gutjnl-2018-316451 · Cited by 353
Saeidi, A., Zandi, K., Cheok, Y. Y., Saeidi, H., Wong, W. F., Lee, C. Y. Q., Cheong, H. C., Yong, Y. K., Larsson, M., & Shankar, E. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02569 · Cited by 350
Microenvironmental Determinants of Pancreatic Cancer
Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neesse, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 331
Kurachi, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00744-5 · Cited by 314
Balermpas, P., Michel, Y., Wagenblast, J., Seitz, O., Weiss, C., Rödel, F., Rödel, C., & Fokas, E. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.640 · Cited by 309
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
Schönrich, G., & Raftery, M. J. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00207 · Cited by 275
Rethinking peripheral T cell tolerance: checkpoints across a T cell’s journey
ElTanbouly, M. A., & Noelle, R. J. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00454-2 · Cited by 265
Kishton, R. J., Barnes, C. E., Nichols, A. G., Cohen, S., Gerriets, V. A., Siska, P. J., Macintyre, A. N., Goraksha-Hicks, P., de Cubas, A. A., Liu, T., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.008 · Cited by 260
Kummer, M. P., Ising, C., Kummer, C., Sarlus, H., Griep, A., Vieira‐Saecker, A., Schwartz, S., Halle, A., Brückner, M., Händler, K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108662 · Cited by 127
“PD-1 upholds CD36 expression, an important factor concerning the microglial uptake of aggregated A b (Yamanaka et al , 2012; Sheedy et al , 2013; Zinselmeyer et al , 2013).”
PD‐1 suppresses TCR‐CD8 cooperativity during T‐cell antigen recognition
Li, K., Yuan, Z., Lyu, J., Ahn, E., Davis, S. J., Ahmed, R., & Zhu, C. (2021) · Nature Communications · doi:10.1038/s41467-021-22965-9 · Cited by 81
Self-citation
Metadata
- Authors
- Zinselmeyer, B. H., Heydari, S., Sacristán, C., Nayak, D., Cammer, M., Herz, J., Cheng, X., Davis, S. J., Dustin, M. L., & McGavern, D. B.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-03-25
- Volume
- 210
- Issue
- 4
- Pages
- 757-774
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2141131774
- Cited by
- 258
- References
- 71
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.